Active Immunization Against Trichophyton Purpureum Infection in Rabbits

Wharton, Martha L.; Reiss, Frederick; Wharton, D. R. A.

doi:10.1038/jid.1950.36

Cited by 20 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apart from the nature of the antigens, the route of administration may have substantial importance on the type or degree of immunity conferred. Intramuscular, subcutaneous and intradermal routes were reported and all were shown to induce some degree of immunity 34–37 . The intradermal route is empirically considered more appropriate by some authors.…”

Section: Discussionmentioning

confidence: 99%

A recombinant 31.5 kDa keratinase and a crude exo‐antigen fromMicrosporum canisfail to protect against a homologous experimental infection in guinea pigs

Descamps

Brouta

Vermout

et al. 2003

Veterinary Dermatology

View full text Add to dashboard Cite

A Microsporum canis recombinant 31.5 kDa keratinase and a M. canis crude exo-antigen were tested as vaccines in an experimental infection model in guinea pigs. Animals were vaccinated subcutaneously three times at two-week intervals with either the keratinase, the exo-antigen or the adjuvant alone. Cutaneous challenge was performed blindly. Both humoral and cellular-specific immune responses to M. canis antigens were evaluated every 14 days, while a blind evaluation of clinical lesion development and fungal persistency in skin were monitored weekly. Vaccination induced very high and significant (P < 0.01) antibody responses towards both antigens. High cell-mediated immune responses to both immunogens were also induced by vaccination. After challenge, however, scores reflecting the severity of dermatophytic lesions did not differ significantly between vaccinated and control groups at any time after challenge. These results suggest that, in the guinea pig, the induction of specific immune responses against the M. canis-secreted antigens used in this study are not protective against challenge exposure.

show abstract

Section: Discussionmentioning

confidence: 99%

A recombinant 31.5 kDa keratinase and a crude exo‐antigen fromMicrosporum canisfail to protect against a homologous experimental infection in guinea pigs

Descamps

Brouta

Vermout

et al. 2003

Veterinary Dermatology

View full text Add to dashboard Cite

show abstract

“…Later, Wharton et al (238) detected precipitins in sera of rabbits experimentally infected with Tnchophyton purpureum or immunized with killed suspensions of this species. They found that resistance to reinfection decreased with disappearance of precipitins.…”

Section: Antibodiesmentioning

confidence: 99%

Immunology of dermatophytes and dermatophytosis.

Grappel¹,

Bishop²,

Blank³

1974

Bacteriological Reviews

View full text Add to dashboard Cite

“…Prior attempts to prevent or limit dermatophytosis with immunization of experimental animals have met with varying success, perhaps in no small part because of wide variation in antigen preparations, immunization protocols, adjuvants, host species, fungal species, and challenge protocols used. Thus, Wharton et al (25) demonstrated successful immunization of rabbits by injection of killed dermatophyte material in any of several oil-wax adjuvants, whereas Reiss and Leonard (26) were unable to repeat this success using guinea pigs. Early studies of the immunity to reinfection that is induced by a primary infection also differed in methods and conclusions (27)(28)(29).…”

Section: Discussionmentioning

confidence: 99%

“…It is possible that the route of administration of a dermatophyte vaccine may have substantial influence on the type or degree of immunity conferred. Intramuscular (15,31), subcutaneous (25,32,33), and intradermal (26,32) routes of vaccine administration have been reported, and all routes have been shown to induce some degree of immunity. A review of the literature reveals that there has been little systematic comparison of the immune response produced by different routes of inoculation.…”

Section: Discussionmentioning

confidence: 99%

The Immune Response toMicrosporum canisInduced by a Fungal Cell Wall Vaccine*

DeBoer

Moriello

1994

Veterinary Dermatology

View full text Add to dashboard Cite

An experimental infection model was used to assess induction of specific immunity against Microsporum canis in cats with an M . canis cell wall vaccine preparation. Kittens 8-9 weeks old (n = 12) received five doses of either vaccine or placebo at biweekly intervals. Specific immunity was monitored via plasma anti-dermatophyte antibody titers and lymphocyte blastogenesis (LB) to dermatophyte antigens. After vaccination, cats were chauenged with viable M . canis spores, and lesion development was monitored. Vaccinated cats developed higher anti-dermatophyte IgG, but not IgM, titers than controls, beginning after the second dose of vaccine (P < 0.001). During the vaccination period, specific cellular immunity as measured by LB was absent in control cats, but developed to a limited degree in vaccinated cats (P < 0.05).After challenge with lo5 fungal spores per cat, both control and vaccinated cats developed active infections.The vaccine appeared to induce an antibody titer quantitatively similar to that produced by infection, but less measured cellular immunity than was seen with infection and recovery. These results suggest that induction of high titers of serum IgG or IgM antibody against Microsporum canis is not protective against challenge exposure.

show abstract

Active Immunization Against Trichophyton Purpureum Infection in Rabbits

Cited by 20 publications

References 15 publications

A recombinant 31.5 kDa keratinase and a crude exo‐antigen fromMicrosporum canisfail to protect against a homologous experimental infection in guinea pigs

A recombinant 31.5 kDa keratinase and a crude exo‐antigen fromMicrosporum canisfail to protect against a homologous experimental infection in guinea pigs

Immunology of dermatophytes and dermatophytosis.

The Immune Response toMicrosporum canisInduced by a Fungal Cell Wall Vaccine*

Contact Info

Product

Resources

About